Chest
Selected ReportsLong-term Effects of Epoprostenol on the Pulmonary Vasculature in Idiopathic Pulmonary Arterial Hypertension
Section snippets
Case Report
The patient was a 53-year-old woman who presented with unexplained dyspnea at age 31 in 1987. A thorough evaluation revealed IPAH as the etiology. She had an elevated pulmonary arterial pressure and pulmonary vascular resistance at cardiac catheterization (Table 1) but was found to be nonvasoreactive to vasodilator challenge and was managed conservatively. In 1991, the patient entered the pivotal clinical trial of epoprostenol for IPAH3 and was randomized to active therapy, which she remained
Histopathologic Findings of the Pulmonary Circulation
The small- to medium-sized pulmonary arteries demonstrated severe muscular hypertrophy and intimal fibrosis with occasional complete occlusion of the lumen. There were frequent plexiform lesions adjacent to arterial branch points, most of which had associated vascular dilatation (Fig 1). Immunostaining revealed the presence of occasional small platelet thrombi and a mild inflammatory infiltrate in the plexiform lesions consisting of CD4+ and CD8+ T cells, CD68+ macrophages, and rare CD20+ B
Discussion
There are several treatments approved specifically for PAH.1 Although all are vasodilators, each class of treatment has been demonstrated to have some degree of antiproliferative effect on vascular smooth muscle cells either in vitro or in animal models of PAH.9, 10, 11 Although clinical trials have demonstrated that they have only modest effects on lowering the pulmonary arterial pressure, it has been proposed that the long-term use of these therapies may reverse some of the pulmonary vascular
Acknowledgments
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Gomberg-Maitland has received research grant support from Actelion, Gilead, Lilly/Icos, Novartis, Pfizer, and United Therapeutics and has served as a consultant for Biomarin, Gilead, Medtronic, Millenium, and Pfizer. She does not do any promotional speaking and has received honoraria from ABcomm and HealthmattersCME for continuing medical education-related events. She has a patent
References (28)
- et al.
Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling
J Am Coll Cardiol
(1992) The current treatment of pulmonary arterial hypertension: time to redefine success
Chest
(2006)- et al.
Pathologic regression of primary pulmonary hypertension in left native lung following right single-lung transplantation
J Heart Lung Transplant
(2001) - et al.
Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation
Chest
(2006) - et al.
The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
J Am Coll Cardiol
(1999) Concentric versus eccentric remodeling
J Card Fail
(2002)- et al.
Prostacyclin stimulation of dog arterial cyclic AMP levels
Prostaglandins
(1979) - et al.
Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol
J Am Coll Cardiol
(2005) - et al.
Treatment of pulmonary arterial hypertension
N Engl J Med
(2004) - et al.
Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
Nat Med
(2000)
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
N Engl J Med
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy
Circulation
Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension
Circ Heart Fail
Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension
Am J Pathol
Cited by (0)
Funding/Support: This work is supported by National Institutes of Health [grants RO1-HL071115 and 1RC1HL099462-01], the American Heart Association, and the Roche Foundation for Anemia Research (to Dr Archer).
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).